Glutamate and Excitatory Amino Acid Neurotransmission

Glutamate is the principal excitatory neurotransmitter of the central nervous system, driving most fast synaptic excitation and underlying synaptic plasticity such as long-term potentiation. It acts through ionotropic receptors (NMDA, AMPA, and kainate types) and a family of metabotropic glutamate receptors, and its signalling must be tightly controlled because excessive activation can be excitotoxic.

Definition

Glutamatergic neurotransmission is fast excitatory signalling by the amino acid glutamate, which acts through ionotropic receptors (NMDA, AMPA, and kainate ligand-gated channels) and metabotropic (G-protein-coupled) glutamate receptors, and is cleared from the synapse by excitatory amino-acid transporters.

Scope

The topic covers glutamate's ionotropic and metabotropic receptor families, its role in synaptic plasticity, the transporters that clear it, and the concept of excitotoxicity. It frames glutamatergic signalling as reference knowledge in CNS pharmacology and as the target of emerging psychiatric and neurological drug strategies, without offering treatment guidance.

Core questions

• How does glutamate produce fast excitatory signalling?
• What distinguishes NMDA, AMPA, and kainate ionotropic receptors?
• How do glutamate receptors mediate synaptic plasticity?
• What is excitotoxicity and why must glutamate be tightly regulated?

Key concepts

• Glutamate as the principal excitatory transmitter
• Ionotropic receptors: NMDA, AMPA, kainate
• Metabotropic glutamate receptors
• Long-term potentiation and synaptic plasticity
• Excitotoxicity
• Excitatory amino-acid transporters

Key theories

NMDA-receptor coincidence detection and plasticity

The account that the NMDA receptor, by requiring both glutamate binding and postsynaptic depolarisation to relieve its magnesium block, acts as a coincidence detector underlying activity-dependent synaptic strengthening such as long-term potentiation.

Glutamate hypotheses of psychiatric illness

The hypotheses that altered glutamatergic, particularly NMDA-receptor, signalling contributes to schizophrenia and to mood disorders, motivating glutamate-targeted therapeutic research.

Mechanisms

Released glutamate binds ionotropic receptors that are cation channels: AMPA receptors mediate fast depolarisation, while NMDA receptors are both ligand- and voltage-gated and are permeable to calcium, allowing them to act as coincidence detectors that trigger plasticity, as detailed by Traynelis et al. (2010). Metabotropic glutamate receptors, reviewed by Niswender and Conn (2010), are G-protein-coupled and modulate excitability and transmitter release over slower timescales. Glutamate is cleared by excitatory amino-acid transporters, largely on astrocytes; failure of this clearance allows excessive receptor activation and calcium influx, the basis of excitotoxic injury. Because of glutamate's central role, altered signalling has been proposed in schizophrenia (Moghaddam & Javitt, 2012) and in depression (Sanacora et al., 2012).

Clinical relevance

Glutamatergic mechanisms are implicated in epilepsy, in excitotoxic neuronal injury, and in psychiatric conditions, and glutamate receptors are an active target for drug development. This entry describes those mechanisms and hypotheses as reference material on signalling; it does not advise on diagnosing, selecting, or dosing any treatment.

Evidence & guidelines

Glutamate receptor classification follows IUPHAR consensus nomenclature; the cited Pharmacological Reviews (Traynelis et al., 2010) and Annual Review (Niswender & Conn, 2010) articles provide the authoritative receptor descriptions used here.

History

Although amino acids were long viewed as metabolic rather than signalling molecules, glutamate was established as the dominant excitatory transmitter in the late twentieth century. The characterisation of the NMDA receptor and its role in long-term potentiation linked glutamate to learning and memory, while the recognition of excitotoxicity and glutamate hypotheses of psychiatric illness extended its importance into neurology and psychiatry.

Debates

How central is glutamatergic dysfunction to schizophrenia?

The glutamate hypothesis, prompted partly by the psychotomimetic effects of NMDA-receptor antagonists, competes and overlaps with dopaminergic accounts; its precise causal role and therapeutic implications remain under investigation.

Seminal works

• traynelis-2010
• niswender-conn-2010
• moghaddam-javitt-2012

Frequently asked questions

Why is glutamate called the main excitatory neurotransmitter?

Because glutamate drives most fast excitatory synaptic transmission in the brain, acting through cation-permeable ionotropic receptors that depolarise target neurons, balancing the inhibition provided by GABA.

What is excitotoxicity?

Excitotoxicity is injury or death of neurons caused by excessive glutamate-receptor activation, particularly through calcium entry via NMDA receptors when glutamate is not adequately cleared from the synapse.